• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌阵挛运动作为治疗剂量氯米帕明治疗的副作用。

Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine.

作者信息

Casas M, Garcia-Ribera C, Alvarez E, Udina C, Queralto J M, Grau J M

机构信息

Department of Psychiatry, Hospital de la Santa Creu i Sant Pau (Medical School), Barcelona, Spain.

出版信息

Int Clin Psychopharmacol. 1987 Oct;2(4):333-6. doi: 10.1097/00004850-198710000-00006.

DOI:10.1097/00004850-198710000-00006
PMID:3693873
Abstract

Myoclonic movements have been observed in depressed patients receiving therapeutic doses of clomipramine. Such movements, which appear in states of deep muscular relaxation such as sleep, do not appear to have any repercussion in the outcome of the depression and are reversible following withdrawal of the drug. In this study the plasma levels of clomipramine and desmethylclomipramine were determined and their possible relationship with myoclonus studied. No statistically significant relationships were found.

摘要

在接受治疗剂量氯米帕明的抑郁症患者中观察到了肌阵挛运动。这种运动出现在深度肌肉放松状态下,如睡眠时,似乎对抑郁症的转归没有任何影响,并且在停药后是可逆的。在本研究中,测定了氯米帕明和去甲氯米帕明的血浆水平,并研究了它们与肌阵挛的可能关系。未发现具有统计学意义的关系。

相似文献

1
Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine.肌阵挛运动作为治疗剂量氯米帕明治疗的副作用。
Int Clin Psychopharmacol. 1987 Oct;2(4):333-6. doi: 10.1097/00004850-198710000-00006.
2
Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.氯米帕明:强迫症患者的血药浓度、副作用及疗效
Postgrad Med J. 1980;56 Suppl 1:134-9.
3
Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients.
Postgrad Med J. 1980;56 Suppl 1:130-3.
4
Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
Eur J Clin Pharmacol. 1992;43(4):405-11. doi: 10.1007/BF02220617.
5
A clinical trial of a 50 mg formulation of clomipramine (Anafranil) with steady-state plasma level measurements.
J Int Med Res. 1977;5(1 Suppl):119-24.
6
Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.氯米帕明用于接受暴露疗法的强迫仪式行为患者:剂量、血药浓度、疗效及副作用之间的关系
Psychopharmacology (Berl). 1988;95(1):113-8. doi: 10.1007/BF00212778.
7
Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
Postgrad Med J. 1980;56 Suppl 1:140-3.
8
The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.血浆氯米帕明和去甲氯米帕明与强迫症反应的关系。
Psychopharmacol Bull. 1990;26(1):119-22.
9
Plasma levels and clinical improvement--a comparative study of clomipramine and amitriptyline in depression.
Postgrad Med J. 1980;56 Suppl 1:127-9.
10
Relationships between clinical response, plasma levels and side-effects of clomipramine (Anafranil) in general practitioner trials.全科医生试验中氯米帕明(安拿芬尼)的临床反应、血浆水平与副作用之间的关系。
J Int Med Res. 1977;5(1 Suppl):108-18.

引用本文的文献

1
The clinical heterogeneity of drug-induced myoclonus: an illustrated review.药物性肌阵挛的临床异质性:图文并茂的综述
J Neurol. 2017 Aug;264(8):1559-1566. doi: 10.1007/s00415-016-8357-z. Epub 2016 Dec 16.
2
Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management.不宁腿综合征相关的抑郁障碍:流行病学、病理生理学和管理。
CNS Drugs. 2010 Feb;24(2):89-98. doi: 10.2165/11317500-000000000-00000.
3
[Restless legs syndrome, periodic limb movements, and psychopharmacology].[不宁腿综合征、周期性肢体运动与精神药理学]
Nervenarzt. 2008 Nov;79(11):1263-4, 1266-72. doi: 10.1007/s00115-008-2575-2.
4
Drug-induced myoclonus: frequency, mechanisms and management.药物性肌阵挛:发生率、机制及处理
CNS Drugs. 2004;18(2):93-104. doi: 10.2165/00023210-200418020-00003.
5
Drug-induced movement disorders.药物性运动障碍
Drug Saf. 1997 Mar;16(3):180-204. doi: 10.2165/00002018-199716030-00004.